- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.12.24 | Alpha Tau Medical Ltd.: Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day | 3 | GlobeNewswire (USA) | ||
| 17.12.24 | Alpha Tau Medical Ltd.: Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor | 1 | GlobeNewswire (USA) | ||
| 17.12.24 | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.12.24 | Alpha Tau Medical Ltd.: Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium | 1 | GlobeNewswire (USA) | ||
| 06.12.24 | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 19.11.24 | Alpha Tau Medical GAAP EPS of -$0.32 | 5 | Seeking Alpha | ||
| 19.11.24 | Alpha Tau Medical Ltd.: Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update | 44 | GlobeNewswire (Europe) | - Alpha DaRT® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market access to the Alpha DaRT® for patients with recurrent glioblastoma multiforme... ► Artikel lesen | |
| ALPHA TAU MEDICAL Aktie jetzt für 0€ handeln | |||||
| 13.11.24 | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 21.10.24 | Alpha Tau Medical Ltd.: Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT for Patients with Recurrent Glioblastoma Multiforme | 123 | GlobeNewswire (Europe) | JERUSALEM, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-emitters cancer therapy Alpha DaRT®... ► Artikel lesen | |
| 21.10.24 | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 11.10.24 | Alpha Tau Medical-Aktien behalten Buy-Rating von H.C. Wainwright | 1 | Investing.com Deutsch | ||
| 11.10.24 | Alpha Tau Medical shares maintain Buy rating from H.C. Wainwright | 1 | Investing.com | ||
| 10.10.24 | Alpha Tau Medical Ltd.: Alpha Tau Treats First Patient with Recurrent Lung Cancer | 1 | GlobeNewswire (USA) | ||
| 10.10.24 | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 20.09.24 | Alpha Tau Medical Ltd.: Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT in Immunocompromised Patients with Recurrent cSCC | 114 | GlobeNewswire (Europe) | JERUSALEM, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®... ► Artikel lesen | |
| 20.09.24 | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.08.24 | Alpha Tau Medical Ltd.: Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the ... | 1 | GlobeNewswire (USA) | ||
| 22.08.24 | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 21.08.24 | Alpha Tau Medical stock holds Buy rating on clinical trial updates | 1 | Investing.com | ||
| 14.08.24 | Alpha Tau Medical Ltd.: Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update | 232 | GlobeNewswire (Europe) | - First patient treated in May for liver metastases from colorectal cancer - - Publication in June in Cancers journal of long-term safety and efficacy data in multiple hard-to-treat superficial cancers... ► Artikel lesen |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PROGYNY | 22,020 | 0,00 % | Witness A Substantial Acquisition As DEBRA MORRIS Acquires Progyny Stock Options Worth $37K | ||
| GERRESHEIMER | 66,05 | +3,12 % | EQS-PVR: Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Gerresheimer AG
Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of... ► Artikel lesen | |
| FRESENIUS | 36,870 | +0,19 % | Leichte Zugewinne bei der Fresenius SE & Co. KGaA-Aktie (36,58 €) | Das Wertpapier von Fresenius SE & Co. KGaA notiert heute fester. Der jüngste Kurs betrug 36,58 Euro. Die Fresenius+Co KgaA-Aktie verzeichnet gegenwärtig einen Wertanstieg von 2,75 Prozent. Sie hat sich... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 56,75 | +6,87 % | Medizintechnik: Carl Zeiss Meditec im Aufwind | Über fünf Prozent Kursplus verbuchte Carl Zeiss Meditec am Donnerstag Vormittag und erklomm zwischenzeitlich den höchsten Stand seit Mitte Dezember - nachdem die Aktie allerdings im vergangenen Jahr... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 53,96 | -0,70 % | UBS stuft Siemens Healthineers auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Siemens Healthineers mit einem Kursziel von 53 Euro auf "Neutral" belassen. Im europäischen Medizintechnik-Bereich gebe... ► Artikel lesen | |
| GENEDX | 77,66 | 0,00 % | GeneDx Announces Preliminary 2024 Financial Results | STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for... ► Artikel lesen | |
| ATRICURE | 40,370 | 0,00 % | Why AtriCure, Inc. (ATRC) Is Skyrocketing Now | ||
| FRESENIUS MEDICAL CARE | 46,400 | -0,45 % | Fresenius Medical Care Aktie: Richtung stimmt! | Die Fresenius Medical Care-Aktie setzt ihren positiven Trend fort und verzeichnet am 19. Januar 2025 einen Kursanstieg von 0,04 Prozent auf 44,88 EUR. Die Entwicklung der vergangenen Wochen zeigt eine... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 7,990 | 0,00 % | LifeStance Health Group, Inc.: LifeStance Reports Third Quarter 2024 Results | SCOTTSDALE, Ariz., Nov. 07, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 69,58 | 0,00 % | PROCEPT BioRobotics (NASDAQ:PRCT) Trading Down 2.8% - Should You Sell? | ||
| BRIGHTSPRING HEALTH SERVICES | 21,555 | 0,00 % | BrightSpring Health Services, Inc. Enters into Definitive Agreement to Divest Community Living Business to Sevita; Reports Preliminary 2024 Financial Results and Provides 2025 Guidance Excluding Community Living | Streamlined organization and Provider Services segment to optimize resource allocationProvider Services focus on Home Health/Hospice, Personal Care, Rehabilitation Services, and Care Management strategic... ► Artikel lesen | |
| ECKERT & ZIEGLER | 51,95 | +3,28 % | AKTIONÄR-Tipp Telix Pharma: Zulassung - darum profitiert auch Eckert & Ziegler | In den USA wird das radiopharmazeutische Diagnostik-Produkt Illuccix bereits regelrecht aus den Regalen gerissen. Entwickler Telix Pharma kann den Top-Seller nun auch in Europa auf den Markt bringen.... ► Artikel lesen | |
| INTUITIVE SURGICAL | 569,80 | -2,38 % | Soll ich diese Aktien jetzt kaufen? Intel, Intuitive Surgical und UnitedHealth im Check | In der neuesten Folge von "Money Train" begrüßen wir Martin Weiß, stellvertretender Chefredakteur bei DER AKTIONÄR. Gemeinsam analysieren wir die aktuelle Lage bei Intel, Intuitive Surgical und UnitedHealth... ► Artikel lesen | |
| TALKSPACE | 3,190 | 0,00 % | Espresa Partners with Talkspace to Boost Employee Well-Being with Accessible Mental Health Benefits | Espresa has partnered with Talkspace to expand mental health support for employees. Through Espresa's platform, clients now have access to Talkspace's 5,000+ licensed therapists, offering secure, on-demand... ► Artikel lesen | |
| NANO-X IMAGING | 8,740 | 0,00 % | Nano-X Imaging LTD.: Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication | Nanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdominal and paranasal indications, in addition to its previously cleared indication... ► Artikel lesen |
ALPHA TAU MEDICAL LTD gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,060 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALPHA TAU MEDICAL LTD finden Sie auf Wallstreet Online.
